#1 Clinical Trials Search in Europe

Omp66

This article explores the ongoing clinical trials of EO2463, a groundbreaking cancer vaccine therapy being tested for patients with indolent Non-Hodgkin’s Lymphoma. The study aims to evaluate the safety, efficacy, and potential combinations of EO2463 with other treatments like lenalidomide and rituximab. This innovative approach could offer new hope for patients with Follicular Lymphoma and Marginal Zone Lymphoma.

Table of Contents

What is EO2463?

EO2463 is a new type of cancer treatment called a microbial-derived peptide therapeutic vaccine. It is currently being studied for the treatment of certain types of indolent Non-Hodgkin’s Lymphoma (NHL), specifically Follicular Lymphoma (FL) and Marginal Zone Lymphoma (MZL).[1]

This innovative therapy is composed of five key components: UCP2, OMP72, OMP64, OMP65, and OMP66. These are all proteins that have been carefully selected to target specific aspects of lymphoma cells.[1]

Target Conditions

EO2463 is being developed to treat two specific types of indolent (slow-growing) Non-Hodgkin’s Lymphoma:

  • Follicular Lymphoma (FL): A type of lymphoma that develops from B-lymphocytes and typically grows slowly.
  • Marginal Zone Lymphoma (MZL): Another slow-growing lymphoma that can occur in several forms, including:
    • Extranodal MZL (EMZL, also known as MALT lymphoma)
    • Splenic MZL (SMZL)
    • Nodal MZL (NMZL)

These lymphomas are considered “indolent” because they tend to grow and spread slowly, often not causing symptoms for a long time.[1]

How EO2463 Works

EO2463 is designed to stimulate the patient’s immune system to recognize and attack lymphoma cells. It works by:

  1. Introducing specific peptides (small protein fragments) that resemble parts of lymphoma cells
  2. Training the immune system, particularly T cells, to recognize these peptides
  3. Encouraging the immune system to attack cells displaying these peptides, which should be the lymphoma cells

The vaccine targets specific B-cell antigens, including CD20, CD22, CD37, and BAFF-receptor, which are commonly found on lymphoma cells.[1]

Clinical Trial Details

EO2463 is currently being studied in a Phase 1/2 clinical trial. This trial is designed to:

  • Determine the safe and effective dose of EO2463 (Phase 1)
  • Evaluate how well EO2463 works in treating indolent NHL (Phase 2)
  • Study EO2463 alone and in combination with other drugs (lenalidomide and rituximab)

The trial includes several patient groups (cohorts) to test different treatment approaches:[1]

  1. EO2463 alone in previously treated patients
  2. EO2463 alone in untreated patients
  3. EO2463 followed by rituximab in untreated patients
  4. EO2463 with lenalidomide and rituximab in previously treated patients

Potential Benefits

The researchers hope that EO2463 will provide several benefits for patients with indolent NHL:

  • Improved response rates to treatment
  • Longer-lasting remissions
  • Potentially fewer side effects compared to traditional chemotherapy
  • A new option for patients who have not responded well to other treatments

The trial will measure these benefits by looking at factors such as the objective response rate (ORR), duration of response (DOR), time to next anti-lymphoma therapy (TTT), progression-free survival (PFS), and overall survival (OS).[1]

Safety Considerations

As with any new treatment, safety is a primary concern. The trial will closely monitor patients for:

  • Side effects (adverse events)
  • Changes in blood cell counts and immune system function
  • Any unexpected reactions to the vaccine

Patients will be followed for up to 5 years after treatment to assess long-term safety.[1]

Eligibility Criteria

To participate in this trial, patients must meet certain criteria, including:

  • Being 18 years or older
  • Having confirmed FL or MZL
  • Being HLA-A2 positive (a specific genetic marker)
  • Having measurable disease
  • Meeting specific health requirements

There are also several factors that may exclude a patient from participating, such as certain prior treatments, other medical conditions, or pregnancy.[1]

If you’re interested in this trial, it’s important to discuss your eligibility with your healthcare provider, who can provide more detailed information about whether this study might be appropriate for you.

Aspect Details
Study Drug EO2463 (novel microbial-derived peptide therapeutic vaccine)
Target Condition Indolent Non-Hodgkin’s Lymphoma (Follicular Lymphoma and Marginal Zone Lymphoma)
Study Phase Phase 1/2
Primary Objectives Determine recommended Phase 2 dose, assess safety, evaluate objective response rate
Treatment Combinations EO2463 alone, with lenalidomide, with rituximab, or with both lenalidomide and rituximab
Key Eligibility Criteria Age ≥18, HLA-A2 positive, specific lymphoma diagnoses
Study Duration 9-12 months active treatment, 24 months short-term follow-up, 5 years long-term follow-up
Key Assessments Safety, efficacy, immunogenicity, changes in B and T cell levels

FAQ

  • What is EO2463 and how does it work? EO2463 is a novel microbial-derived peptide therapeutic vaccine being tested for the treatment of indolent Non-Hodgkin's Lymphoma. It works by stimulating the immune system to target specific proteins found on cancer cells, potentially helping the body fight the lymphoma more effectively.
  • Who is eligible to participate in this clinical trial? Eligibility varies by cohort, but generally includes patients aged 18 or older with indolent Non-Hodgkin's Lymphoma (specifically Follicular Lymphoma or Marginal Zone Lymphoma), who are HLA-A2 positive. Some cohorts require previously treated patients, while others focus on newly diagnosed cases.
  • What are the main objectives of this clinical trial? The main objectives are to determine the recommended dose of EO2463, assess its safety when used alone or in combination with other drugs, and evaluate its effectiveness in treating indolent Non-Hodgkin's Lymphoma by measuring the objective response rate in patients.
  • How long does the treatment and follow-up last? The active treatment period lasts between 9 to 12 months, depending on the cohort. After treatment, there is a 24-month short-term follow-up period, followed by a 5-year long-term safety follow-up with check-ups every 6 months.
  • What are some potential side effects or risks of participating in this trial? While specific side effects are not detailed in the provided information, the trial closely monitors for adverse events, treatment-emergent adverse events, and any serious adverse events. Patients with certain medical conditions or a history of autoimmune disorders may be excluded to minimize risks.

Ongoing Clinical Trials on Omp66

  • Study of EO2463, Lenalidomide, and Rituximab for Patients with Indolent Non-Hodgkin’s Lymphoma

    Recruiting

    2 1 1 1
    Investigated diseases:
    Investigated drugs:
    France Italy Spain

Glossary

  • Indolent Non-Hodgkin's Lymphoma: A slow-growing type of cancer that affects the lymphatic system, including subtypes like Follicular Lymphoma and Marginal Zone Lymphoma.
  • EO2463: A novel microbial-derived peptide therapeutic vaccine being tested for the treatment of indolent Non-Hodgkin's Lymphoma.
  • Follicular Lymphoma (FL): A type of indolent Non-Hodgkin's Lymphoma that develops from B-lymphocytes and typically grows slowly.
  • Marginal Zone Lymphoma (MZL): Another type of indolent Non-Hodgkin's Lymphoma that affects B-lymphocytes, often found in the spleen, lymph nodes, or mucosa-associated lymphoid tissue.
  • Lenalidomide: An immunomodulatory drug used in combination with EO2463 in some cohorts of the clinical trial.
  • Rituximab: A monoclonal antibody therapy used to treat certain types of blood cancers, including Non-Hodgkin's Lymphoma.
  • HLA-A2: A specific type of human leukocyte antigen (HLA) that patients must possess to be eligible for this clinical trial.
  • Objective Response Rate (ORR): A measure of how well a cancer responds to treatment, typically assessed by the reduction in tumor size or number of cancer cells.
  • Recommended Phase 2 Dose (RP2D): The optimal dose of a drug determined during the phase 1 part of a clinical trial, which will be used in subsequent phases.
  • Progression-Free Survival (PFS): The length of time during and after treatment that a patient lives with the disease without it worsening.
  • Overall Survival (OS): The length of time from the start of treatment or diagnosis that patients are still alive.
  • ECOG Performance Status: A scale used to assess how a patient's disease is progressing and how it affects daily living abilities.
  • Ann Arbor Staging: A system used to describe the extent of lymphoma in a patient's body, with stages ranging from I to IV.
  • GELF Criteria: Guidelines used to determine tumor burden in lymphoma patients, which can influence treatment decisions.

References

  1. http://clinicaltrials.eu/trial/study-of-eo2463-lenalidomide-and-rituximab-for-patients-with-indolent-non-hodgkins-lymphoma/